Enzymit team (company pic)
Enzymit is an Israeli biochemical startup developing cell-free enzymatic manufacturing technology. The firm closed a $10 million Series A funding round, which was led by Grove Ventures and Khosla Ventures, with participation from previous investors First Star Ventures and Sapir Venture Partners.
Enzymatic is an adjective used to describe something related to or produced by enzymes. Enzymes are biological catalysts that accelerate chemical reactions. They are essential for life, as they enable countless biochemical processes to occur at rates that would otherwise be too slow to sustain life.
Enzymes are typically proteins, but some RNA molecules can also act as enzymes. These RNA enzymes are called ribozymes.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
Enzymes have a very specific shape, which is essential for their function. The shape of an enzyme allows it to bind to specific molecules called substrates. When an enzyme binds to its substrate, it can catalyze a chemical reaction that converts the substrate into a product.
Enzymes are found in all living organisms, from bacteria to humans. They are involved in a wide variety of biological processes, including digestion, metabolism, and cell signaling.
Founded in 2020 by Dr. Gideon Lapidoth and COO Dror Baran, experts in computational science, Enzymit uses deep learning algorithms and high-throughput testing methods to develop novel enzymes for various applications such as fine chemical manufacturing, foodtech, health, biodefense and more. Our team collaborates with global manufacturers across multiple industries, driving both expansion and market impact.
“For decades, bio-production has been limited by the search for natural enzymes that might fit industrial needs,” said Dr. Gideon Lapidoth, CEO and co-founder of Enzymit. “Our AI-powered platform changes this paradigm by designing entirely new enzymes tailored for specific production challenges. This enables us to create the molecules and materials that were previously unattainable or prohibitively costly to produce.”
“The Series A funding will enable us to establish our pilot facility and begin scaling production for global distribution,” said Dror Baran, Enzymit’s COO and co-founder “Cell-free bio-production technology offers a timely solution. We’re not only making bio-production affordable; we’re fundamentally transforming how products are made.”
